Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | The potential of targeting CD123 in myeloid malignancies

Anand Patel • 6 Jun 2023
ASCO 2023
Acute Myeloid Leukemia Leukemia CAR-NK CAR-T SAR443579 Tagraxofusp

Anand Patel, MD, University of Chicago, Chicago, IL, discusses the potential of targeting CD123 with immunotherapy in myeloid malignancies, highlighting promising CD123-targeting agents such as SAR443579, a natural killer (NK) cell engager currently under evaluation in an early phase clinical trial. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anand Patel

4:22
Accelerated-phase MPNs: pathophysiology, treatment approaches and ongoing clinical trials
Anand Patel • 6 Jun 2023
4:36
COMMANDS: luspatercept versus epoetin alfa in LR-MDS-associated anemia - results & caveats
Anand Patel • 6 Jun 2023
2:33
Insights into the results and implications of the COMMANDS & IMerge studies in LR-MDS
Anand Patel • 6 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals